Can less be more? new trial aims to reduce side effects in testicular cancer treatment
NCT ID NCT03937843
First seen Jan 25, 2026 · Last updated Jun 21, 2026 · Updated 19 times
Summary
This phase 2 trial tests whether reducing the intensity of chemotherapy and radiation can safely treat stage IIA/B seminoma, a type of testicular cancer. About 135 patients will receive either carboplatin alone or a combination of cisplatin and etoposide, along with lower-dose radiotherapy. The goal is to maintain cancer control while minimizing long-term side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TESTICULAR CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASKLEPIOS Kliniken
Hamburg, 22763, Germany
-
Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, CH-1011, Switzerland
-
Evang. Kliniken Essen-Mitte
Essen, 45136, Germany
-
Helios Klinikum Berlin-Buch
Berlin, 13125, Germany
-
Hopital de Sion
Sion, 1951, Switzerland
-
Inselspital Bern
Bern, 3010, Switzerland
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, CH-6500, Switzerland
-
Kantonsspital - St. Gallen
Sankt Gallen, CH-9007, Switzerland
-
Kantonsspital Graubuenden
Chur, 7000, Switzerland
-
Kantonsspital Graubünden
Chur, 7000, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
RKH Klinikum Ludwigsburg
Ludwigsburg, 71640, Germany
-
Rotkreuzklinikum München
München, München, 80364, Germany
-
Universitaetsspital-Basel
Basel, CH-4031, Switzerland
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Universitätsklinikum Ulm
Ulm, 89075, Germany
-
Vivantes Klinikum Am Urban
Berlin, 10967, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, cisplatin, and etoposide
What this could lead to
If successful, this could offer a safer treatment option for stage IIA/B seminoma with fewer side effects while still controlling the cancer.
What could go wrong
This is a phase 2 trial with only 135 participants, so results may not apply to all patients. Lowering treatment intensity could risk cancer recurrence.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.